Claims
- 1. A method of modulating the inflammatory response in cells, the method comprising contacting the cells with a composition comprising a fraction isolated or derived from hops.
- 2. A method of treating or inhibiting a pathological condition in a mammal associated with tissue-specific activation of inflammation, the method comprising administering to the mammal a composition comprising a fraction derived from hops.
- 3. The method of claim 2, wherein the fraction derived from hops is selected from the group consisting of isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids, and spent hops.
- 4. The method of claim 2, wherein the fraction derived from hops comprises a compound of a supragenus having the formula:
- 5. The method of claim 2, wherein the fraction derived from hops comprises a compound of Genus A having the formula:
- 6. The method of claim 2, wherein the fraction derived from hops comprises a compound of Genus B having the formula:
- 7. The method of claim 2, wherein the fraction derived from hops comprises a compound selected from the group consisting of cohumulone, adhumulone, isohumulone, isocohumulone, isoadhumulone, dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.
- 8. The method of claim 2, wherein the composition comprises about 0.5 to 10000 mg of the fraction derived from hops.
- 9. The method of claim 8, wherein the composition comprises about 50 to 7500 mg of the fraction derived from hops.
- 10. The method of claim 2, wherein the composition comprises about 0.001 to 10 weight percent of the fraction derived from hops.
- 11. The method of claim 10, wherein the composition comprises about 0.1 to 1 weight percent of the fraction derived from hops.
- 12. The method of claim 2, wherein the pathological condition is selected from the group consisting of autoimmune diseases, inflammatory diseases, neurological diseases, and cancer.
- 13. The method of claim 2, wherein the pathological condition is selected from the group consisting of inflammation, inflammation-associated disorders, arthritis, asthma, bronchitis, menstrual cramps, tendonitis, bursitis, skin-related conditions, gastrointestinal conditions, cancer, ophthalmic diseases, pulmonary inflammation, nervous system disorders, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, and central nervous damage.
- 14. The method of claim 2, wherein the composition further comprises a pharmaceutically acceptable carrier.
- 15. The method of claim 2, wherein the composition is administered orally, topically, parenterally, or rectally.
- 16. A method of modulating the amount of cyclooxygenase-2 (COX-2) activity in target cells without substantially modulating COX-2 activity in non-target cells, the method comprising contacting the cells with a fraction derived from hops.
- 17. The method of claim 16, wherein the non-target cells are also contacted with said fraction derived from hops.
- 18. The method of claim 16, wherein the contacting step is in vivo.
- 19. The method of claim 16, wherein the COX-2 activity is modulated by inhibition of COX-2 gene.
- 20. A method of treating or inhibiting a pathological condition in a mammal involving inhibiting inducibility or activity of cyclooxygenase-2 (COX-2), the method comprising administering to the mammal a composition comprising a fraction derived from hops.
- 21. The method of claim 20, wherein the fraction derived from hops is selected from the group consisting of isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids, and spent hops.
- 22. The method of claim 20, wherein the fraction derived from hops comprises a compound of a supragenus having the formula:
- 23. The method of claim 20, wherein the fraction derived from hops comprises a compound of Genus A having the formula:
- 24. The method of claim 20, wherein the fraction derived from hops comprises a compound of Genus B having the formula:
- 25. The method of claim 20, wherein the fraction derived from hops comprises a compound selected from the group consisting of cohumulone, adhumulone, isohumulone, isocohumulone, isoadhumulone, dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.
- 26. The method of claim 20, wherein the pathological condition is selected from the group consisting of wherein the pathological condition is selected from the group consisting of inflammation, inflammation-associated disorders, arthritis, asthma, bronchitis, menstrual cramps, tendonitis, bursitis, skin-related conditions, gastrointestinal conditions, cancer, ophthalmic diseases, pulmonary inflammation, nervous system disorders, allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome, atherosclerosis, and central nervous damage.
- 27. The method of claim 20, wherein the composition further comprises a pharmaceutically acceptable carrier.
- 28. The method of claim 20, wherein the composition is administered orally, topically, parenterally, or rectally.
- 29. A method of inhibiting prostaglandin synthesis selectively in target cells, the method comprising contacting the cells with a fraction derived from hops.
- 30. The method of claim 29, wherein the fraction derived from hops is selected from the group consisting of-isoalpha acids, reduced isoalpha acids, tetra-hydroisoalpha acids, hexa-hydroisoalpha acids, beta acids, and spent hops.
- 31. The method of claim 29, wherein the fraction derived from hops comprises a compound of a supragenus having the formula:
- 32. The method of claim 29, wherein the fraction derived from hops comprises a compound of Genus A having the formula:
- 33. The method of claim 29, wherein the fraction derived from hops comprises a compound of Genus B having the formula:
- 34. The method of claim 29, wherein the fraction derived from hops comprises a compound selected from the group consisting of cohumulone, adhumulone, isohumulone, isocohumulone, isoadhumulone, dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, and hexahydro-adhumulone.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This patent application is a continuation-in-part of U.S. application Ser. No. 10/400,293, filed Mar. 26, 2003, and a continuation-in-part of U.S. application Ser. No. 10/401,283, filed Mar. 26, 2003, both of which claim the benefit under 35 U.S.C. § 119(e) to provisional application No. 60/450,237, filed on Feb. 25, 2003, and provisional application No. 60/420,383, filed on Oct. 21, 2002. This application is also a continuation-in-part of U.S. application Ser. No. 09/885,721, filed Jun. 20, 2001. The contents of each of these earlier applications are hereby incorporated by reference as if recited herein in their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60450237 |
Feb 2003 |
US |
|
60420383 |
Oct 2002 |
US |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
10400293 |
Mar 2003 |
US |
Child |
10464834 |
Jun 2003 |
US |
Parent |
10401283 |
Mar 2003 |
US |
Child |
10464834 |
Jun 2003 |
US |
Parent |
09885721 |
Jun 2001 |
US |
Child |
10464834 |
Jun 2003 |
US |